Elsie Biotechnologies Inc. logo

Elsie Biotechnologies Inc.

2 Marks
Corp.
First Filed:Aug 8, 2022Latest Filed:Aug 8, 2022Address:10355 Science Center Drive, Suite 110, San Diego, CA 92121

Portfolio Overview

Pending
2(100%)

Top Classes

Class 5
Pharmaceuticals
2(100%)
Class 40
Material Treatment
2(100%)
Class 42
Software, IT Services & Scientific Research
2(100%)

TTAB Proceedings

No litigation activity

Top Firms

GlaxoSmithKline(Aug 2022)
2

Trademark Portfolio

2 results

(current & previous marks)

Refine by Mark/Description🔽
Filed
Registered
Last Activity
ELSIE BIOTECHNOLOGIES
PENDING
Owner:
Serial:97539845
Filed:Aug 8, 2022
Classes:1, 5, 40, +1
Goods & Services
Custom manufacture of oligonucleotides; Oligonucleotide compounds for use as pharmaceutical therapies prescribed or administered by a physician for the treatment of a wide variety of conditions and illnesses; Oligonucleotide delivery agents that facilitate delivery of a wide range of pharmaceutical therapies prescribed or administered by a physician; Oligonucleotide-based or -derived pharmaceuticals prescribed or administered by a physician for the treatment of a wide variety of conditions and illnesses; Pharmaceuticals prescribed or administered by a physician comprised of oligonucleotide compounds for the treatment of a wide variety of conditions and illnesses; Oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents prescribed or administered by a physician; drug delivery agents consisting of oligonucleotide compounds that facilitate delivery of a wide range of pharmaceuticals prescribed or administered by a physician; Oligonucleotide compounds for use in the manufacture of pharmaceutical therapies; "BIOTECHNOLOGIES"; Research and development of oligonucleotide compounds for use in pharmaceutical therapies; Research and development of oligonucleotide delivery agents for use in pharmaceutical therapies; Research and development of oligonucleotide-based or -derived pharmaceuticals; Research and development of pharmaceuticals comprised of oligonucleotide compounds; Research and development of oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents; Research and development of drug delivery agents consisting of oligonucleotide compounds
X
X
Trademark
Combined
PENDING
Owner:
Serial:97539827
Filed:Aug 8, 2022
Classes:1, 5, 40, +1
Goods & Services
Custom manufacture of oligonucleotides; Oligonucleotide compounds for use as pharmaceutical therapies for the treatment of a wide variety of conditions and illnesses; Oligonucleotide delivery agents that facilitate delivery of a wide range of pharmaceutical therapies; Oligonucleotide-based or -derived pharmaceuticals for the treatment of a wide variety of conditions and illnesses; Pharmaceuticals comprised of oligonucleotide compounds for the treatment of a wide variety of conditions and illnesses ; Oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents; Drug delivery agents consisting of oligonucleotide compounds that facilitate delivery of a wide range of pharmaceuticals; Oligonucleotide compounds for use in the manufacture of pharmaceutical therapies; Research and development of oligonucleotide compounds for use in pharmaceutical therapies; Research and development of oligonucleotide delivery agents for use in pharmaceutical therapies; Research and development of oligonucleotide-based or -derived pharmaceuticals; Research and development of pharmaceuticals comprised of oligonucleotide compounds; Research and development of oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents; Research and development of drug delivery agents consisting of oligonucleotide compounds

Cookie Preferences

We use cookies (including Google Analytics) to improve our site and understand how visitors use it.